查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1854752

依藥物類別、治療類型和給藥途徑分類的開放性青光眼藥物市場－2025-2032年全球預測

Open-Angle Glaucoma Therapeutics Market by Drug Class, Therapy Type, Route Of Administration - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，開放性青光眼藥物市場規模將達到 187.3 億美元，複合年成長率為 9.06%。

關鍵市場統計數據
基準年 2024 93.5億美元
預計年份：2025年 102.2億美元
預測年份 2032 187.3億美元
複合年成長率 (%) 9.06%

這是一本簡明權威的說明，介紹了不斷變化的治療格局、未滿足的需求以及影響開角型青光眼治療的戰略要務。

開放性青光眼仍然是全球不可逆性視力喪失的主要原因，藥物研發也在不斷發展，以滿足尚未滿足的臨床需求並適應技術進步。近年來，該領域的研究方法已從單純關注眼壓轉向多方面策略，這些策略涵蓋神經保護、患者依從性和聯合治療。這拓寬了臨床醫生和支付方在將新藥和給藥方法應用於臨床實踐時所評估的證據基礎。

新型作用機制的引入、持續給藥系統的進步以及對真實世界療效的日益關注，共同重塑了臨床預期和商業模式。因此，製藥、生物技術和醫療設備行業的相關人員正在重新評估其市場推廣計劃、證據生成策略和夥伴關係。本導言重點在於將定義近期治療格局的變革性轉變、監管環境和交易動態、市場區隔細微差別、區域性考量以及策略行動。

機制創新、先進的給藥技術以及不斷變化的支付方期望如何從根本上改變開放性青光眼的治療策略和應用

在科學、臨床和商業性力量的共同推動下，開放性青光眼的治療模式正在經歷一場變革。機制創新，特別是Rho激酶抑制劑和其他標靶海綿竇房結流出藥物的出現，正在挑戰傳統治療類別的長期主導地位，並亟需進行直接的療效比較評估。同時，藥物製劑和給藥方式的改進，包括緩釋性植入和不含防腐劑的局部用藥，正在重塑患者的用藥依從性和臨床實踐。

同時，支付方的期望和監管路徑也在不斷演變，這促使人們更加重視可靠的真實世界證據和衛生經濟學評估。診斷技術的創新，例如增強型影像和家庭監測技術，使得早期發現疾病和更個人化的治療調整成為可能。研發開發平臺優先考慮那些已證實具有持久性和耐受性優勢的藥物，商業模式強調病患支援和依從性解決方案，而製藥和醫療設備製造商之間為提供整合式醫療解決方案而開展的合作也日益普遍。

2025年關稅主導的供應鏈轉變及其對維持治療藥物可近性、連續性和商業性發展勢頭的戰略應對措施的實際影響

2025年新關稅的實施將為依賴全球採購的零件和原料藥的治療藥物和醫療設備帶來額外的商業性複雜性。更高的進口關稅可能會增加原料和成品的到岸成本，迫使採購團隊重新評估其供應商組合，並考慮雙重採購和本地化策略，以維持利潤率和供應的連續性。為此，一些製造商正在加速推動近岸外包和製造外包合作，以降低關稅波動帶來的風險。

關稅不僅影響直接成本，還會影響策略時間表和產品上市順序。企業可能會調整其供應鏈佈局，優先選擇貿易摩擦較小的市場，或保護關鍵生產線免受關稅相關干擾。在這種環境下，長期供應協議和價格調整條款等合約保護措施的重要性也日益凸顯。從臨床角度來看，關稅可能透過提高藥品標價或限制某些進口製劑的供應，間接影響患者的用藥，因此需要擴大患者援助計畫並進行靈活的報銷談判。總而言之，關稅情勢凸顯了製定動態商業策略的必要性，這些策略應整合貿易風險評估、供應鏈韌性和積極的相關人員參與。

基於藥物類別、治療類型和給藥途徑的細分證據優先事項和商業化途徑，塑造了治療差異化。

對細分市場的深入理解對於根據藥物類別、治療類型和給藥途徑對資產進行定位，以及確定臨床和商業投資的優先順序至關重要。在藥物類別方面，需要考慮的包括α促效劑、 BETA阻斷劑、碳酸酐酶抑制劑、複方製劑、前列腺素類似物和Rho激酶抑制劑。在BETA阻斷劑方面，需要考慮的包括倍他洛爾、美替洛爾和噻嗎洛爾；在前列腺素類似物方面，需要考慮的包括Bimatoprost、拉坦前列素、他氟前列素和曲伏前列素。這些區分至關重要，因為機制特異性的安全性和耐受性特徵以及差異化潛力會影響臨床定位和處方討論。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 緩釋性微針眼內植入在數月內持續控制眼內壓的應用日益增加。
  • 擴大微創青光眼手術與新一代藥物傳遞系統的應用
  • 開發並推出 Rho 激酶抑制劑，作為First-in-Class治療藥物
  • 增加對旨在長期調控房水流出途徑的基因治療方法的投資
  • 提高依從性可增加固定劑量Bimatoprost和奈他舒地爾複方組合藥物的滲透率。
  • 將家庭眼壓監測與人工智慧演算法結合，實現個人化青光眼管理的數位健康平台正在湧現。
  • 生技公司與眼科領域領導者加強策略夥伴關係，共同開發新型肽類療法

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依藥物類別分類的開放性青光眼藥物市場

  • α-促效劑
  • BETA受體阻斷劑
    • 倍他洛爾
    • 美替洛爾
    • 噻嗎洛爾
  • 碳酸酐酶抑制劑
  • 固定劑量組合
  • 前列腺素類似物
    • Bimatoprost
    • 拉坦前列素
    • 他氟前列素
    • 曲伏前列素
  • Rho激酶抑制劑

第9章 依治療類型開放性青光眼治療市場

  • 聯合治療
    • BETA受體阻斷劑與攝護腺素
    • 碳酸酐酶抑制劑和BETA阻斷劑
  • 單藥治療

第10章 依給藥途徑分類的開放性青光眼藥物市場

  • 靜脈
  • 口服
  • 局部的

第11章 各地區開放性青光眼治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 按組別分類的開放性青光眼治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國開放性青光眼治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Novartis AG
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Santen Pharmaceutical Co., Ltd.
    • Aerie Pharmaceuticals, Inc.
    • Alcon Inc.
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-957C47F9384B

The Open-Angle Glaucoma Therapeutics Market is projected to grow by USD 18.73 billion at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.35 billion
Estimated Year [2025] USD 10.22 billion
Forecast Year [2032] USD 18.73 billion
CAGR (%) 9.06%

A concise and authoritative orientation to the evolving therapeutic landscape, unmet needs, and strategic imperatives shaping open-angle glaucoma care

Open-angle glaucoma remains a leading cause of irreversible vision loss worldwide, and therapeutics development continues to evolve in response to unmet clinical needs and technological progress. In recent years, the field has witnessed a shift from solely intraocular pressure-centric approaches to multidimensional strategies that consider neuroprotection, patient adherence, and combination regimens. This has broadened the evidence base that clinicians and payers evaluate when integrating new agents and delivery modalities into practice.

The introduction of novel mechanisms of action, advances in sustained-delivery systems, and an expanding emphasis on real-world outcomes have collectively reshaped clinical expectations and commercial models. Consequently, stakeholders across pharmaceutical, biotechnology, and medical device sectors are re-evaluating go-to-market plans, evidence-generation strategies, and partnerships. This introduction sets the stage for a focused exploration of the transformative shifts, regulatory and trade dynamics, segmentation nuances, regional considerations, and strategic actions that will define the therapeutic landscape in the near term.

How mechanistic innovation, advanced delivery technologies, and evolving payer expectations are fundamentally reshaping open-angle glaucoma therapeutic strategy and adoption

The therapeutic landscape for open-angle glaucoma is undergoing transformative shifts driven by converging scientific, clinical, and commercial forces. Mechanistic innovation, particularly the emergence of Rho kinase inhibitors and other agents targeting trabecular outflow, challenges the long-standing dominance of traditional classes and invites head-to-head comparative effectiveness assessments. At the same time, improvements in drug formulation and delivery - including sustained-release implants and preservative-free topical options - are reshaping adherence patterns and clinical practice.

Concurrently, payer expectations and regulatory pathways are evolving, incentivizing robust real-world evidence and health-economic evaluations. Innovations in diagnostics, such as enhanced imaging and home-monitoring technologies, are enabling earlier detection and more individualized treatment adjustments. These combined trends are prompting a strategic realignment across life sciences companies and clinics: research and development pipelines are being prioritized for agents with demonstrable durability and tolerability advantages, commercial models are emphasizing patient support and adherence solutions, and partnerships between pharmaceutical and device manufacturers are becoming more common to deliver integrated care solutions.

Practical implications of tariff-driven supply chain shifts in 2025 and strategic responses that preserve access, continuity, and commercial momentum for therapeutics

The imposition of new tariffs in 2025 has introduced an additional layer of commercial complexity for therapeutics and devices that rely on globally sourced components and active pharmaceutical ingredients. Increased duties on imports can elevate the landed cost of raw materials and finished products, prompting procurement teams to reassess supplier portfolios and consider dual sourcing or regionalization strategies to preserve margin and supply continuity. In response, some manufacturers are accelerating nearshoring and contract manufacturing partnerships to mitigate exposure to tariff volatility.

Beyond direct cost impacts, tariffs influence strategic timelines and product launch sequencing. Companies may adjust supply chain footprints to prioritize markets with lower trade friction or to insulate critical production lines from tariff-related disruptions. This environment also amplifies the importance of contractual protections, such as long-term supply agreements and price adjustment clauses. From a clinical perspective, tariffs can indirectly affect access by increasing list prices or constraining the availability of certain imported formulations, thereby necessitating expanded patient assistance programs and adaptive reimbursement negotiations. Overall, the tariff landscape underscores the need for dynamic commercial strategies that integrate trade risk assessment, supply chain resilience, and proactive stakeholder engagement.

Segment-specific evidence priorities and commercialization levers drawn from drug classes, therapy types, and administration routes that shape therapeutic differentiation

A nuanced understanding of segmentation is essential to position assets and prioritize clinical and commercial investments across drug classes, therapy types, and routes of administration. Based on drug class, study considerations span Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors, Fixed Dose Combinations, Prostaglandin Analogues, and Rho Kinase Inhibitors, with the Beta Blockers category further disaggregated into Betaxolol, Metipranolol, and Timolol, and Prostaglandin Analogues examined across Bimatoprost, Latanoprost, Tafluprost, and Travoprost. These distinctions matter because mechanism-specific safety and tolerability profiles, as well as differentiation potential, influence clinical positioning and formulary discussions.

Based on therapy type, the market perspective encompasses Combination Therapy and Monotherapy, where Combination Therapy merits closer scrutiny for regimens such as Beta Blocker And Prostaglandin and Carbonic Anhydrase Inhibitor And Beta Blocker. Combination strategies often seek to improve intraocular pressure control while simplifying regimens to enhance adherence, which can materially affect real-world effectiveness. Based on route of administration, the clinical and commercial dialogue must address Intravenous, Oral, and Topical approaches, each of which carries unique considerations for delivery technology, patient acceptance, safety monitoring, and distribution logistics. Taken together, segmentation insights should drive targeted evidence generation and commercial differentiation for any candidate therapy.

How regional regulatory nuances, payer frameworks, and supply chain dynamics across the Americas, EMEA, and Asia-Pacific inform differentiated market entry and growth strategies

Regional dynamics materially influence regulatory pathways, reimbursement approaches, and commercial execution, requiring tailored strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, pricing negotiations, payer contracting, and patient support infrastructure are critical determinants of access and uptake, while clinical practice patterns and ophthalmology referral networks shape the adoption curve for new mechanisms and sustained-delivery systems.

In Europe, Middle East & Africa, diverse regulatory regimes and reimbursement criteria necessitate robust health-economic dossiers and region-specific real-world evidence. Market entry strategies must account for heterogeneous procurement processes and variable hospital purchasing practices across countries. In the Asia-Pacific region, regulatory modernization, growing biotech investment, and a rising focus on locally manufactured products create opportunities for collaboration and regional manufacturing. Across all geographies, supply chain resilience, local clinical data generation, and culturally attuned patient support programs are core enablers of sustained adoption and commercial success.

Competitive positioning and partnership models that enable durable differentiation across pharmaceutical, biotech, and device stakeholders in glaucoma therapeutics

Competitive dynamics in the open-angle glaucoma therapeutics space are shaped by a mix of large pharmaceutical companies, specialty biotechs, and device-focused manufacturers, each pursuing distinct routes to clinical and commercial differentiation. Established players typically leverage broad distribution networks, clinical trial experience, and payer relationships to support incremental innovations and lifecycle management. In contrast, smaller biotechs emphasize single-mechanism breakthroughs, nimble development timelines, and strategic partnerships to de-risk scale-up and access pathways.

Collaboration models are increasingly prevalent: co-development and licensing agreements bring together formulation expertise, delivery platforms, and commercialization capabilities. Meanwhile, device manufacturers that deliver sustained-release implants or novel administration systems are collaborating with drug developers to offer integrated solutions that address adherence and durability. Successful companies are those that align clinical development with pragmatic evidence generation, engage early with payers and key opinion leaders, and invest in patient-centric support services that reinforce real-world outcomes and reduce treatment discontinuation.

High-impact, actionable recommendations for R&D prioritization, commercial planning, and supply chain resilience to accelerate adoption and protect access

Industry leaders should pursue a coordinated strategy that aligns scientific differentiation with commercial execution and supply chain resilience. Prioritize development programs that address clear tolerability or adherence advantages over existing standards of care and design clinical trials to capture endpoints meaningful to clinicians, payers, and patients. This includes integrating quality-of-life measures and adherence metrics into pivotal studies and planning for real-world evidence generation from the outset.

From a commercial perspective, invest in patient support systems, clinician education, and value demonstration to build compelling reimbursement narratives. Strengthen supplier relationships and diversify manufacturing footprints to mitigate tariff and trade risks, and evaluate regional manufacturing or contract development and manufacturing organization partnerships where appropriate. Pursue strategic collaborations that combine delivery technology with pharmacologic innovation, and engage payers early to align on evidence requirements and pricing strategies. Finally, maintain adaptive launch sequencing and portfolio prioritization that reflects regional regulatory timelines, procurement environments, and local clinical practice patterns.

Transparent and reproducible research methods combining expert primary interviews and comprehensive secondary evidence to inform strategic decision-making

The report synthesizes primary and secondary research methods to create a robust, triangulated evidence base. Primary research included structured interviews with clinicians, payers, procurement specialists, and industry executives, complemented by advisory-board consultations and field-level insights from commercial teams. Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to contextualize clinical development trends and market-access drivers.

Data from these sources were triangulated to reconcile differing perspectives and validate strategic conclusions. Quality-control measures included cross-validation of interview findings, reproducibility checks for analytical models, and a governance process for expert review. Where gaps existed, targeted follow-up interviews were conducted to ensure the analysis reflected current practice and regulatory dynamics. The methodology emphasizes transparency and reproducibility while prioritizing practical insights that inform clinical development, commercialization, and policy strategy.

A conclusive synthesis of therapeutic innovation, evidence priorities, and operational imperatives that leaders must address to translate advances into sustained clinical and commercial success

In summary, the open-angle glaucoma therapeutics landscape is entering a phase where mechanistic innovation, delivery advances, and evolving payer expectations converge to create both opportunity and complexity. Companies that integrate differentiated clinical value with durable delivery solutions and robust real-world evidence will be best positioned to influence clinical practice and secure reimbursement. Simultaneously, trade dynamics and regional heterogeneity require proactive supply chain planning and localized market strategies.

Achieving sustained impact will depend on aligning R&D priorities with pragmatic evidence generation, engaging stakeholders across the care pathway early, and deploying patient-centric commercial programs that support adherence and long-term outcomes. Decision-makers who adopt an integrated approach-combining scientific differentiation, commercial rigor, and operational resilience-will be able to translate therapeutic innovation into improved patient care and durable business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of sustained-release microneedle ocular implants for continuous IOP control over months
  • 5.2. Expanding usage of minimally invasive glaucoma surgery combined with next generation drug delivery systems
  • 5.3. Development and commercial launch of Rho kinase inhibitors as first-in-class therapy targeting trabecular meshwork
  • 5.4. Growing investment in gene therapy approaches for long-term modulation of aqueous humor outflow pathways
  • 5.5. Increasing penetration of fixed-dose bimatoprost and netarsudil combinations driven by adherence benefits
  • 5.6. Emergence of digital health platforms integrating home tonometry and AI algorithms for personalized glaucoma management
  • 5.7. Escalating strategic partnerships between biotech firms and ophthalmology leaders for novel peptide therapeutics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Open-Angle Glaucoma Therapeutics Market, by Drug Class

  • 8.1. Alpha Agonists
  • 8.2. Beta Blockers
    • 8.2.1. Betaxolol
    • 8.2.2. Metipranolol
    • 8.2.3. Timolol
  • 8.3. Carbonic Anhydrase Inhibitors
  • 8.4. Fixed Dose Combinations
  • 8.5. Prostaglandin Analogues
    • 8.5.1. Bimatoprost
    • 8.5.2. Latanoprost
    • 8.5.3. Tafluprost
    • 8.5.4. Travoprost
  • 8.6. Rho Kinase Inhibitors

9. Open-Angle Glaucoma Therapeutics Market, by Therapy Type

  • 9.1. Combination Therapy
    • 9.1.1. Beta Blocker And Prostaglandin
    • 9.1.2. Carbonic Anhydrase Inhibitor And Beta Blocker
  • 9.2. Monotherapy

10. Open-Angle Glaucoma Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Topical

11. Open-Angle Glaucoma Therapeutics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Open-Angle Glaucoma Therapeutics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Open-Angle Glaucoma Therapeutics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. AbbVie Inc.
    • 14.3.2. Novartis AG
    • 14.3.3. Pfizer Inc.
    • 14.3.4. Merck & Co., Inc.
    • 14.3.5. Santen Pharmaceutical Co., Ltd.
    • 14.3.6. Aerie Pharmaceuticals, Inc.
    • 14.3.7. Alcon Inc.
    • 14.3.8. Viatris Inc.
    • 14.3.9. Teva Pharmaceutical Industries Ltd.
    • 14.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 272. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD MILLION)
  • TABLE 273. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 274. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 275. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2025-2032 (USD